324 related articles for article (PubMed ID: 16505416)
41. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
[TBL] [Abstract][Full Text] [Related]
42. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
43. Poor outcome in estrogen receptor-positive breast cancers predicted by loss of plexin B1.
Rody A; Holtrich U; Gaetje R; Gehrmann M; Engels K; von Minckwitz G; Loibl S; Diallo-Danebrock R; Ruckhäberle E; Metzler D; Ahr A; Solbach C; Karn T; Kaufmann M
Clin Cancer Res; 2007 Feb; 13(4):1115-22. PubMed ID: 17317819
[TBL] [Abstract][Full Text] [Related]
44. Cyclin D1 expression is associated with poor prognostic features in estrogen receptor positive breast cancer.
Aaltonen K; Amini RM; Landberg G; Eerola H; Aittomäki K; Heikkilä P; Nevanlinna H; Blomqvist C
Breast Cancer Res Treat; 2009 Jan; 113(1):75-82. PubMed ID: 18240019
[TBL] [Abstract][Full Text] [Related]
45. Integrated gene expression profile predicts prognosis of breast cancer patients.
Li LF; Xu XJ; Zhao Y; Liu ZB; Shen ZZ; Jin WR; Shao ZM
Breast Cancer Res Treat; 2009 Jan; 113(2):231-7. PubMed ID: 18278552
[TBL] [Abstract][Full Text] [Related]
46. 17beta-hydroxysteroid dehydrogenase 14 affects estradiol levels in breast cancer cells and is a prognostic marker in estrogen receptor-positive breast cancer.
Jansson AK; Gunnarsson C; Cohen M; Sivik T; Stål O
Cancer Res; 2006 Dec; 66(23):11471-7. PubMed ID: 17145895
[TBL] [Abstract][Full Text] [Related]
47. Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis.
Mehra R; Varambally S; Ding L; Shen R; Sabel MS; Ghosh D; Chinnaiyan AM; Kleer CG
Cancer Res; 2005 Dec; 65(24):11259-64. PubMed ID: 16357129
[TBL] [Abstract][Full Text] [Related]
48. The importance of temporal effects in evaluating the prognostic impact of joint ERPR expression in premenopausal women with node-positive breast cancer.
Ouyang Y; Li D; Pater JL; Levine M
Breast Cancer Res Treat; 2005 Jul; 92(2):115-23. PubMed ID: 15986120
[TBL] [Abstract][Full Text] [Related]
49. [Gene expression profiling of ER+ breast cancers: to discriminate the poor prognosis tumors or to define the most suitable treatment?].
Chanrion M; Darbon JM
Bull Cancer; 2008 May; 95(5):513-8. PubMed ID: 18541515
[TBL] [Abstract][Full Text] [Related]
50. Characterization of breast cancer subtypes by quantitative assessment of biological parameters: relationship with clinicopathological characteristics, biological features and prognosis.
Del Casar JM; Martín A; García C; Corte MD; Alvarez A; Junquera S; González LO; Bongera M; García-Muñiz JL; Allende MT; Vizoso F
Eur J Obstet Gynecol Reprod Biol; 2008 Dec; 141(2):147-52. PubMed ID: 18768247
[TBL] [Abstract][Full Text] [Related]
51. Estrogen receptor alpha positive breast tumors and breast cancer cell lines share similarities in their transcriptome data structures.
Zhu Y; Wang A; Liu MC; Zwart A; Lee RY; Gallagher A; Wang Y; Miller WR; Dixon JM; Clarke R
Int J Oncol; 2006 Dec; 29(6):1581-9. PubMed ID: 17089000
[TBL] [Abstract][Full Text] [Related]
52. Differentially expressed genes and estrogen receptor status in breast cancer.
Nagai MA; Ros N; Bessa SA; Mourão Neto M; Miracca EC; Brentani MM
Int J Oncol; 2003 Nov; 23(5):1425-30. PubMed ID: 14532986
[TBL] [Abstract][Full Text] [Related]
53. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns.
Gruvberger S; Ringnér M; Chen Y; Panavally S; Saal LH; Borg A ; Fernö M; Peterson C; Meltzer PS
Cancer Res; 2001 Aug; 61(16):5979-84. PubMed ID: 11507038
[TBL] [Abstract][Full Text] [Related]
54. Molecular subtyping of breast cancer from traditional tumor marker profiles using parallel clustering methods.
Ambrogi F; Biganzoli E; Querzoli P; Ferretti S; Boracchi P; Alberti S; Marubini E; Nenci I
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):781-90. PubMed ID: 16467089
[TBL] [Abstract][Full Text] [Related]
55. Acid ceramidase 1 expression correlates with a better prognosis in ER-positive breast cancer.
Ruckhäberle E; Holtrich U; Engels K; Hanker L; Gätje R; Metzler D; Karn T; Kaufmann M; Rody A
Climacteric; 2009 Dec; 12(6):502-13. PubMed ID: 19905902
[TBL] [Abstract][Full Text] [Related]
56. Meta-analysis of gene expression profiles related to relapse-free survival in 1,079 breast cancer patients.
Györffy B; Schäfer R
Breast Cancer Res Treat; 2009 Dec; 118(3):433-41. PubMed ID: 19052860
[TBL] [Abstract][Full Text] [Related]
57. A prognostic test for adenocarcinoma of the lung from gene expression profiling data.
Gordon GJ; Richards WG; Sugarbaker DJ; Jaklitsch MT; Bueno R
Cancer Epidemiol Biomarkers Prev; 2003 Sep; 12(9):905-10. PubMed ID: 14504202
[TBL] [Abstract][Full Text] [Related]
58. Concordance among gene-expression-based predictors for breast cancer.
Fan C; Oh DS; Wessels L; Weigelt B; Nuyten DS; Nobel AB; van't Veer LJ; Perou CM
N Engl J Med; 2006 Aug; 355(6):560-9. PubMed ID: 16899776
[TBL] [Abstract][Full Text] [Related]
59. RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data.
Győrffy B; Benke Z; Lánczky A; Balázs B; Szállási Z; Timár J; Schäfer R
Breast Cancer Res Treat; 2012 Apr; 132(3):1025-34. PubMed ID: 21773767
[TBL] [Abstract][Full Text] [Related]
60. Molecular classification of estrogen receptor-positive/luminal breast cancers.
Geyer FC; Rodrigues DN; Weigelt B; Reis-Filho JS
Adv Anat Pathol; 2012 Jan; 19(1):39-53. PubMed ID: 22156833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
